Organ damage is a major determinant of work productivity impairment in Behçet's Syndrome: a post-hoc analysis of the BODI validation study

Objectives: To evaluate the prevalence, magnitude, and potential determinants of work productivity impairment in patients with Behçet's Syndrome (BS), focusing on the role of irreversible organ damage. Methods: A post-hoc analysis of the BS overall damage index (BODI) prospective validation study was performed. Demographics and clinical features were recorded in all patients. The Work Productivity and Activity Impairment: General Health (WPAI: GH) questionnaire was administered to assess the work limitation and the BODI to measure organ damage. The independent effect of BS features on WPAI: GH outcomes was evaluated by regression analysis. Results: Out of 148 patients, 34.5% were unemployed, with age (OR 1.035) and BODI score (OR 1.313 for 1-unit increase) as the only factors significantly (p< 0.05) associated with the unemployment state. An overall work impairment was reported in about 64.2% of the employed patients. Indeed, 22.7% reported missing work h due to their health (absenteeism), with a mean time loss of 34.4%; whereas 60.2% declared a reduced performance at work because of their health (presenteeism), with a mean productivity impairment of 45.4%. Ocular damage was associated with absenteeism (β 0.225); female sex (β 0.260), physician global assessment of disease activity (β 0.502) and an increased BODI score (β 0.166 for 1-point increase) with presenteeism; fibromyalgia (β 0.246), physician global assessment (β 0.469), and musculoskeletal damage (β 0.325) with overall work impairment. Conclusions: Disease activity and organ damage accrual remarkably affect work productivity in BS patients. Achieving remission and preventing damage accrual are crucial and complementary objectives

Accrual of organ damage in Behçet's syndrome: trajectory, associated factors, and impact on patients' quality of life over a 2-year prospective follow-up study

Background: This study aimed to investigate the trajectory of damage accrual, associated factors, and impact on health-related quality of life (HR-QoL) in a multicenter cohort of patients with Behcet's syndrome (BS) over 2 years of follow-up.Methods: Patients recruited in the BS Overall Damage Index (BODI) validation study were prospectively monitored for 2 years and assessed for damage accrual, defined as an increase >= 1 in the BODI score, and HR-QoL was evaluated by the SF-36 questionnaire. Logistic and multiple linear regression models were built to determine factors associated with damage accrual and impairment in the different SF-36 domains.Results: During follow-up, 36 out of 189 (19.0%) patients had an increase >= 1 in the BODI score with a mean (SD) difference of 1.7 (0.8) (p <0.001). The incidence rate of damage accrual was stable over time, regardless of the disease duration. Out of 61 new BODI items, 25 (41.0%) were considered related to glucocorticoid (GC) use. In multivariate analysis, duration of GC therapy (OR per 1-year 1.15, 95% CI 1.07-1.23; p <0.001) and occurrence of >= 1 disease relapse (OR 3.15, 95% CI 1.09-9.12; p 0.038) were identified as predictors of damage accrual, whereas the use of immunosuppressants showed a protective effect (OR 0.20, 95% CI 0.08-0.54, p<0.001). Damage accrual was independently associated with the impairment of different physical domains and, to a greater extent, in emotional domains of the SF-36 questionnaire. Female sex, higher disease activity, and fibromyalgia were also significantly associated with impairment in HR-QoL.Conclusion: In BS, organ damage accrues over time, also in long-standing disease, resulting in an impairment of the perceived physical and mental health. Adequate immunosuppressive treatment, preventing disease flares and minimizing exposure to GCs have a crucial role in lowering the risk of damage accrual

Discordance between patient and physician global assessment of disease activity in Behçet's syndrome: a multicenter study cohort

Background: To compare the patients' and physician's global assessment of disease activity in Behçet's syndrome (BS) and investigate the frequency, magnitude, and determinants of potential discordance. Methods: A total of 226 adult BS patients with a median (IQR) age of 46.9 (35.6-55.2) years were enrolled across Italy, Greece, Portugal, and Spain. Demographic, clinical, and therapeutic variables, as well as the patient reported outcomes, were collected at the recruitment visit. The physical (PCS) and mental (MCS) component summary scores of the Short Form Questionnaire 36 (SF-36) and the Behçet's syndrome Overall Damage Index (BODI) were calculated. Disease activity was assessed by the patients' (PtGA) and physician's global assessment (PGA) in a 10-cm visual analog scale, as well as the Behçet Disease Current Activity Form (BDCAF). Discordance (∆) was calculated by subtracting the PGA from the PtGA and defined as positive (PtGA>PGA) and negative (PtGA 80%) of disagreements were due to patients rating higher their disease activity. Higher values of BDCAF were associated to increased rate of positive discordance. When BDCAF = 0, the median (IQR) values of PtGA and PGA were 0.2 (0-2) and 0 (0-1), respectively. PCS (adjusted odds ratio (adjOR) 0.96 per unit, 95% CI 0.93-0.98, p = 0.006) and MCS (adjOR 0.96 per unit, 95% CI 0.93-0.99, p = 0.003) were independently associated with positive discordance using both cutoffs. Active ocular involvement emerged as a potential determinant of negative discordance (adjOR 5.88, 95% CI 1.48-23.30, p = 0.012). Conclusions: PtGA and PGA should be considered as complementary measures in BS, as patients and physicians may be influenced by different factors when assessing active disease manifestations. Particularly, PtGA may be a useful tool in the assessment of BS disease activity, as it carries a low risk to misclassify an inactive disease, and may allow to capture aspects of the patient's health that negatively affect his well-being and the treatment

Music education in Greece and the investigation of the training needs of music teachers

The purpose of this dissertation is to capture the training needs andexpectations of music teachers, so that their lifelong education can be organized based on research data, in order to achieve their professional and personal development and the formation of a modern professional music teacher. In the first part of the dissertation concepts such as adult training, teacher training and teacher professional development were clarified, followed by historical review of Music Education in the Greek educational system from the establishment of the modern Greek state until today, analyzed the profile of Greek music teachers employed in the modern Greek school and in the countries of the European Union and the chapter is completed withtheir training. Subsequently, a survey was conducted on Music teachers working in Primary and Secondary education, in General education and Music schools, throughout Greece, using a questionnaire, which examined the evaluation of their previous experience in training programs, the needs that they consider to be covered by Continuing Education and their personal needs and preferences for thematic areas of training. A total of 484 questionnaires were completed. After analyzing the research results, we observe that Music teachers seem to be dissatisfied with the training programs offered, while at the same time wishing to participate actively in their organization and implementation, showing a preference for flexible programs in subject matter and in the duration of time and seeking the connection between theory and practice.Σκοπός της παρούσας διατριβής είναι η αποτύπωση των επιμορφωτικώναναγκών και προσδοκιών των εκπαιδευτικών Μουσικής, ώστε να μπορεί ναοργανωθεί η δια βίου εκπαίδευσή τους στηριγμένη σε ερευνητικά δεδομένα,προκειμένου να επιτευχθεί η επαγγελματική και προσωπική τους ανάπτυξη και η διαμόρφωση ενός σύγχρονου επαγγελματία εκπαιδευτικού Μουσικής. Στο πρώτο μέρος της διατριβής αποσαφηνίζονται έννοιες όπως επιμόρφωση ενηλίκων, επιμόρφωση εκπαιδευτικών και επαγγελματική ανάπτυξη των εκπαιδευτικών, ακολουθεί μία ιστορική αναδρομή στη Μουσική εκπαίδευση στο ελληνικό εκπαιδευτικό σύστημα από την ίδρυση του νεοελληνικού κράτους μέχρι σήμερα, αναλύεται το προφίλ των εκπαιδευτικών Μουσικής που διδάσκουν στο σύγχρονο ελληνικό σχολείο και στις χώρες της Ευρωπαϊκής Ένωσης και το κεφάλαιο ολοκληρώνεται με την επιμόρφωσή τους. Στη συνέχεια, πραγματοποιήθηκε έρευνα στους εκπαιδευτικούς Μουσικής που εργάζονται στην Πρωτοβάθμια και Δευτεροβάθμια εκπαίδευση, Γενικής παιδείας αλλά και σε Μουσικά σχολεία, σε όλη την ελληνική επικράτεια με την χρήση ερωτηματολογίου, όπου διερευνήθηκαν η αξιολόγηση της προηγούμενης εμπειρίας τους σε προγράμματα επιμόρφωσης, οιανάγκες που θεωρούν ότι καλύπτει η Συνεχιζόμενη εκπαίδευση και οι προσωπικές τους ανάγκες και προτιμήσεις για θεματικούς άξονες επιμόρφωσης. Συνολικά συμπληρώθηκαν 484 ερωτηματολόγια.Μετά από την ανάλυση των ερευνητικών αποτελεσμάτων, διαπιστώνουμε ότιοι εκπαιδευτικοί Μουσικής φαίνεται να μην είναι απόλυτα ικανοποιημένοι από τα προσφερόμενα επιμορφωτικά προγράμματα, ενώ ταυτόχρονα επιθυμούν νασυμμετέχουν ενεργά στην οργάνωση και την υλοποίησή τους, δείχνοντας μίαπροτίμηση προς ευέλικτα προγράμματα και ως προς τη θεματολογία αλλά και την χρονική διάρκεια και επιζητώντας την σύνδεση θεωρίας και πράξης

Cost of illness study and quality of life in Ankylosing Spondyloarthritis patients receiving biological treatments in Greece

The concept of Axial Spa was realized in 2009 by ASAS. It was a result of the need to early recognize and diagnose patients with Ankylosing Spondylitis (AS), which were until then diagnosed according to imaging and clinical criteria of 1984 New York. The use of MRI and the understanding of the role of HLA-B27 contributed to the identification of patients with all the clinical features of AS but without definite radiographic changes. This subgroup of patients was labeled as non-radiographic Axial Spa in contrast to AS which has the characteristic radiographic changes according to New York criteria. Both entities, AS and non-radiographic Axial Spa, are included in Axial Spa, which is a part of a larger family of diseases, the Spondyloarthropathies. As the disease starts usually between the second and third decade of life and has a chronic progression, the impact on quality of life, the ability to perform paid work, and health resources is significant. From a socio-economic point of view, it is important to use therapies that prevent or slow down the progression of the disease, thus avoiding the high economic costs associated with it, the reduction of productivity and the deterioration of the quality of life. The introduction of biological therapies in the treatment of inflammatory diseases has brought impressive results in the course of the disease. However, their increased financial costs compared to conventional treatments question the use of these drugs and therefore pharmacoeconomic studies are needed to prove the effectiveness of such interventions. In this study, we estimated the cost of illness, quality of life and workability among patients with axial Spa treated with biologic agents in Greece. The average annual total cost from the payer’s perspective amounts to € 8,504. The largest part of the cost (~ 87%) is due to the cost of obtaining the biological treatment and then a very significant contribution to the total cost has the administration cost of drugs (11%). From the patient's perspective, the average annual total cost is € 939. Most of the cost (~ 52%) corresponds to the indirect cost, ie the loss of productivity caused by the inability of patients to work as a result of their condition or because relatives have to take a leave to care for them. A significant contribution to the total cost has also the direct non-medical costs (46%), which include the costs of transporting patients to and from the hospital, and home adjustments.Regarding work productivity, an improvement of disease activity as measured with BASDAI is associated with an increase in performance at work. In our study, the mean BASDAI of the patients starting biological treatment decreased from 5.74 to 3.2 after 52 weeks while work productivity loss decreased from 30% to 20% accordingly. Similarly, absenteeism and presenteeism also decreased from 9% and 32% to 5% and 23%. The same positive effect on the work productivity of patients with AS was documented by improving their quality of life. The data collected from the HAQ questionnaires showed a reduction of the scale from 1.13 at baseline to 0.75 at the end of the follow-up period. The HAQ and BASDAI scores according to our regression analysis were the factors with the most important predictive value for the total loss of productivity and therefore for the costs that accompany it.In conclusion, there is a significant cost (direct and indirect) related to the treatment of AS in Greece. Functional impairment is the factor with the most significant cost impact. Biologic therapies that reduce functional impairment can be effective in reducing the cost of Axial SpA and improving the patient's quality of life and reducing stress in the health care system.Η έννοια της Αξονικής Σπονδυλοαρθρίτιδας (Αξ. ΣπΑ) υλοποιήθηκε το 2009 από την ASAS (Assessment of SpondyloArthritis international Society) μια διεθνή ομάδα ειδικών στο πεδίο των Σπονδυλοαρθριτίδων. Ήταν αποτέλεσμα της ανάγκης έγκαιρης αναγνώρισης και διάγνωσης ασθενών με Αγκυλοποιητική Σπονδυλίτιδα (ΑΣ), οι οποίοι μέχρι τότε διαγιγνώσκονταν σύμφωνα με απεικονιστικά και κλινικά κριτήρια της Νέας Υόρκης του 1984. Η χρήση της μαγνητικής τομογραφίας και η κατανόηση του ρόλου του HLA-B27 συνέβαλαν στην ταυτοποίηση ασθενών με όλα τα κλινικά χαρακτηριστικά της ΑΣ αλλά χωρίς σαφείς ακτινογραφικές αλλαγές. Αυτή η υποομάδα ασθενών κατηγοριοποιήθηκε ως μη ακτινογραφική Αξ.ΣπΑ σε αντίθεση με την ΑΣ που έχει τις χαρακτηριστικές ακτινογραφικές βλάβες σύμφωνα με τα κριτήρια της Νέας Υόρκης. Και οι δύο αυτές οντότητες, περιλαμβάνονται στην Αξ. ΣπΑ, η οποία αποτελεί μέρος μιας μεγαλύτερης οικογένειας νοσημάτων, των Σπονδυλοαρθροπαθειών. Καθώς η ασθένεια ξεκινά συνήθως μεταξύ της δεύτερης και της τρίτης δεκαετίας της ζωής και έχει χρόνια εξέλιξη, ο αντίκτυπος στην ποιότητα ζωής, στην ικανότητα εκτέλεσης αμειβόμενης εργασίας και στους πόρους υγείας είναι σημαντικός. Από κοινωνικοοικονομική άποψη, είναι σημαντικό να χρησιμοποιούνται θεραπείες που αποτρέπουν ή επιβραδύνουν την εξέλιξη της νόσου, αποφεύγοντας έτσι το υψηλό οικονομικό κόστος που συνδέεται με αυτήν, τη μείωση της παραγωγικότητας και την υποβάθμιση της ποιότητας ζωής. Η εισαγωγή βιολογικών θεραπειών στη θεραπεία των φλεγμονωδών νοσημάτων έχει φέρει εντυπωσιακά αποτελέσματα στην πορεία της νόσου. Ωστόσο, το αυξημένο οικονομικό κόστος τους σε σύγκριση με τις συμβατικές θεραπείες αμφισβητεί τη χρήση αυτών των φαρμάκων και ως εκ τούτου απαιτούνται φαρμακο-οικονομικές μελέτες για να αποδειχθεί η αποτελεσματικότητα τέτοιων παρεμβάσεων. Σε αυτή τη μελέτη, υπολογίσαμε το κόστος της νόσου, την ποιότητα ζωής και την παραγωγικότητα στην εργασία σε ασθενείς με Αξ. ΣπΑ που έλαβαν θεραπεία με βιολογικούς παράγοντες στην Ελλάδα. Το μέσο ετήσιο συνολικό κόστος από την πλευρά του δημόσιου συστήματος υγείας ανέρχεται σε 8.504 €. Το μεγαλύτερο μέρος του κόστους (~ 87%) οφείλεται στο κόστος απόκτησης της βιολογικής θεραπείας και στη συνέχεια πολύ σημαντική συνεισφορά στο συνολικό κόστος έχει το κόστος χορήγησης των φαρμάκων (~ 11%). Από την πλευρά του ασθενούς, το μέσο ετήσιο συνολικό κόστος είναι 939 €. Το μεγαλύτερο κομμάτι του συγκεκριμένου κόστους (~ 52%) αντιστοιχεί στο έμμεσο κόστος, δηλαδή στην απώλεια παραγωγικότητας που προκαλείται από την αδυναμία εργασίας των ασθενών ως αποτέλεσμα της κατάστασής τους ή λόγω της απασχόλησης τρίτων προσώπων που πρέπει να πάρουν άδεια για να τους φροντίσουν. Σημαντική συνεισφορά στο συνολικό κόστος έχει και το άμεσο μη ιατρικό κόστος (~ 46%), το οποίο περιλαμβάνει το κόστος μεταφοράς ασθενών από και προς το νοσοκομείο καθώς και τις απαραίτητες προσαρμογές στο σπίτι.Όσον αφορά την παραγωγικότητα στην εργασία, η βελτίωση της δραστηριότητας της νόσου όπως μετράται με το BASDAI σχετίζεται με αύξηση της απόδοσης στην εργασία. Στην παρούσα μελέτη, ο μέσος όρος του δείκτη BASDAI των ασθενών που άρχισαν βιολογική θεραπεία μειώθηκε από 5,74 σε 3,2 μετά από 52 εβδομάδες, ενώ η απώλεια παραγωγικότητας εργασίας μειώθηκε από 30% σε 20% αντίστοιχα. Ομοίως, η απουσία και η παρουσία χωρίς την ανάλογη απόδοση, στον εργασιακό χώρο μειώθηκαν επίσης από 9% και 32% σε 5% και 23%. Η ίδια θετική επίδραση στην παραγωγικότητα της εργασίας των ασθενών με Αξ. ΣπΑ τεκμηριώθηκε με τη βελτίωση της ποιότητας ζωής τους. Τα δεδομένα που συλλέχθηκαν από τα ερωτηματολόγια HAQ έδειξαν μείωση της κλίμακας από 1,13 στην αρχική τιμή σε 0,75 στο τέλος της περιόδου παρακολούθησης. Οι βαθμολογίες HAQ και BASDAI σύμφωνα με την ανάλυση παλινδρόμησής ήταν οι παράγοντες με τη σημαντικότερη προγνωστική αξία για τη συνολική απώλεια παραγωγικότητας και συνεπώς για το κόστος που τη συνοδεύει.Συμπερασματικά, υπάρχει σημαντικό κόστος (άμεσο και έμμεσο) που σχετίζεται με τη θεραπεία της Αξ. ΣπΑ στην Ελλάδα. Η έκπτωση της λειτουργικότητας είναι ο παράγοντας με τη σημαντικότερη επίπτωση στο κόστος. Οι βιολογικές θεραπείες που αποδεδειγμένα βελτιώνουν τη λειτουργική ικανότητα μπορεί να είναι αποτελεσματικές στη μείωση του κόστους της νόσου και στη βελτίωση της ποιότητας ζωής του ασθενούς, συντελώντας έτσι και στη μείωση του φόρτου στο σύστημα υγειονομικής περίθαλψης

Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: Case report and review of current clinical evidence

Objective: Rituximab is approved for the treatment of granulomatosis with polyangiitis and microscopic polyangiitis. Our objective was to review published clinical evidence on the efficacy of rituximab in the treatment of eosinophilic granulomatosis and polyangiitis (EGPA). Methods: We describe a case of refractory EGPA with severe vasculitic neuropathy, which responded impressively to B-cell-depleting therapy. A systematic search of the English literature was also performed to capture all available clinical evidence on the use of rituximab in EGPA. Results: We identified a total of 73 EGPA patients who have been treated with rituximab, all data coming from case series or isolated case reports. The majority of patients (85.1%) were treated for refractory or relapsing disease; a mean (SD) of 2.1 (0.9) different immunosuppressive agents were used prior to rituximab administration. Efficacy of RTX therapy was significant in the majority of cases and in a wide variety of disease manifestations; however, a lack of standardized assessment of disease activity before and after treatment was observed in many reports. Overall, 54.0% of patients were treated with a single cycle of rituximab and only 10.8% experienced relapses of the disease. Few significant side effects were observed during a highly variable period of follow-up (3 months to 5 years), mainly severe infections and allergic reactions. Conclusions: RTX seems to be effective in cases of severe EGPA refractory to standard of care immunosuppressive treatment, although support comes from case reports and non-controlled studies. (C) 2015 Elsevier Inc. All rights reserved

Development and preliminary validation of the Behçet’s syndrome Overall Damage Index (BODI)

Objective: To develop and validate the evidence-based and consensus-based Behçet's Syndrome Overall Damage Index (BODI). Methods: Starting from 120 literature-retrieved preliminary items, the BODI underwent multiple Delphi rounds with an international multidisciplinary panel consisting of rheumatologists, internists, ophthalmologists, neurologists, and patient delegates until consensus was reached on the final content. The BODI was validated in a cross-sectional multicentre cohort of 228 patients with Behçet's syndrome (BS) through the study of (a) correlation between BODI and Vasculitis Damage Index (VDI) and (b) correlation between BODI and disease activity measures (ie, Behçet's Disease Current Activity Form (BDCAF), Physician Global Assessment (PGA), Patient Global Assessment (PtGA)), c) content and face validity and (d) feasibility. Results: The final BODI consists of 4 overarching principles and 46 unweighted-items grouped into 9 organ domains. It showed good to excellent reliability, with a mean Cohen's k of 0.84 (95% CI 0.78 to 0.90) and a mean intra-class correlation coefficient of 0.88 (95% CI 0.80 to 0.95). Overall, 128 (56.1%) patients had a BODI score ≥1, with a median score of 1.0 (range 0-14). The BODI significantly correlated with the VDI (r=0.693, p<0.001), demonstrating to effectively measure damage (construct validity), but had greater sensitivity in identifying major organ damage and did not correlate with disease activity measures (ie, BDCAF: p=0.807, PGA: p=0.820, PtGA: p=0.794) discriminating damage from the major confounding factor. The instrument was deemed credible (face validity), complete (content validity) and feasible by an independent group of clinicians. Conclusions: Pending further validation, the BODI may be used to assess organ damage in patients with BS in the context of observational and controlled trials.info:eu-repo/semantics/publishedVersio

Discordance between patient and physician global assessment of disease activity in Behçet's syndrome: a multicenter study cohort

Background: To compare the patients' and physician's global assessment of disease activity in Behçet's syndrome (BS) and investigate the frequency, magnitude, and determinants of potential discordance. Methods: A total of 226 adult BS patients with a median (IQR) age of 46.9 (35.6-55.2) years were enrolled across Italy, Greece, Portugal, and Spain. Demographic, clinical, and therapeutic variables, as well as the patient reported outcomes, were collected at the recruitment visit. The physical (PCS) and mental (MCS) component summary scores of the Short Form Questionnaire 36 (SF-36) and the Behçet's syndrome Overall Damage Index (BODI) were calculated. Disease activity was assessed by the patients' (PtGA) and physician's global assessment (PGA) in a 10-cm visual analog scale, as well as the Behçet Disease Current Activity Form (BDCAF). Discordance (∆) was calculated by subtracting the PGA from the PtGA and defined as positive (PtGA>PGA) and negative (PtGA<PGA) discordance using both a more stringent (∆ = ±2) and a less stringent (∆ = ±1) cutoff. Univariate and multivariate logistic regressions were performed. Results: Median PtGA and PGA scores were 2.0 (0.3-5.0) and 1.0 (0.0-3.0) cm, respectively. The discordance prevalence varied (from 29.6 to 55.3%) according to the cutoff applied, and the majority (> 80%) of disagreements were due to patients rating higher their disease activity. Higher values of BDCAF were associated to increased rate of positive discordance. When BDCAF = 0, the median (IQR) values of PtGA and PGA were 0.2 (0-2) and 0 (0-1), respectively. PCS (adjusted odds ratio (adjOR) 0.96 per unit, 95% CI 0.93-0.98, p = 0.006) and MCS (adjOR 0.96 per unit, 95% CI 0.93-0.99, p = 0.003) were independently associated with positive discordance using both cutoffs. Active ocular involvement emerged as a potential determinant of negative discordance (adjOR 5.88, 95% CI 1.48-23.30, p = 0.012). Conclusions: PtGA and PGA should be considered as complementary measures in BS, as patients and physicians may be influenced by different factors when assessing active disease manifestations. Particularly, PtGA may be a useful tool in the assessment of BS disease activity, as it carries a low risk to misclassify an inactive disease, and may allow to capture aspects of the patient's health that negatively affect his well-being and the treatment.The BODI Project was partly supported by a grant from the Italian Behçet’s Syndrome Patient Association (SIMBA ONLUS).info:eu-repo/semantics/publishedVersio

Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases

Objective tau o report outcomes of breakthrough COVID-19 in comparison with COVID-19 in unvaccinated patients with systemic rheumatic diseases (SRDs). Methods Patients with SRD with COVID-19 (vaccinated and unvaccinated) were included by their rheumatologists in a registry operated by the Greek Rheumatology Society in a voluntarily basis. Type, date and doses of SARS-CoV-2 vaccines were recorded, and demographics, type of SRD, concurrent treatment, comorbidities and COVID-19 outcomes (hospitalisation, need for oxygen supplementation and death) were compared between vaccinated and unvaccinated patients. Results Between 1 March 2020 and 31 August 2021, 195 patients with SRD with COVID-19 were included; 147 unvaccinated and 48 vaccinated with at least one dose of a SARS-CoV-2 vaccine (Pfizer n=38 or AstraZeneca n=10). Among vaccinated patients, 29 developed breakthrough COVID-19 &gt;14 days after the second vaccine dose (fully vaccinated), while 19 between the first and &lt;14 days after the second vaccine dose (partially vaccinated). Despite no differences in demographics, SRD type, treatment or comorbidities between unvaccinated and vaccinated patients, hospitalisation and mortality rates were higher in unvaccinated (29.3% and 4.1%, respectively) compared with partially vaccinated (21% and 0%) or fully vaccinated (10.3% and 0%) patients. Conclusions Vaccinated patients with SRD with breakthrough COVID-19 have better outcomes compared with unvaccinated counterparts with similar disease/treatment characteristics